Table 2 Adherence to PEG-IFN and RBV among the overall population, those on 12 weeks of therapy, and those on 24 weeks of therapy
Variable | Overall (n = 93) | 12 week (n = 61) | 24 week (n = 26) |
|---|---|---|---|
Treatment completion | 71 (76) | 59 (97) | 12 (46) |
Mean on-treatment PEG-IFN adherence percent, (SD) | 98.2 (4.5) | 98.5 (3.1) | 98.7 (3.0) |
Mean on-treatment ribavirin adherence percent, (SD) | 94.6 (8.8) | 94.8 (8.1) | 94.1 (10.8) |
Missed doses of PEG-IFN, n (%) | |||
No missed doses | 87 (94) | 59 (97) | 22 (85) |
1 missed dose | 6 (6) | 2 (3) | 4 (15) |
2–5 missed doses | 0 (0) | 0 (0) | 0 (0) |
> 5 missed doses | 0 (0) | 0 (0) | 0 (0) |
Missed doses of ribavirin, n (%) | |||
100% of doses taken | 22 (25) | 16 (26) | 5 (20) |
95%- < 100% of doses taken | 38 (44) | 25 (41) | 13 (52) |
90%- < 95% of doses taken | 15 (17) | 11 (18) | 4 (16) |
80%- < 90% of doses taken | 7 (8) | 6 (10) | 1 (4) |
< 80% of doses taken | 5 (6) | 3 (5) | 2 (8) |
Number of weeks of PEG-IFN therapy, n (%) | |||
24 weeks | 12 (13) | NA | 12 (46) |
13 to 23 weeks | 3 (3) | NA | 3 (3) |
7 to 12 weeks | 69 (74) | 61 (100) | 8 (31) |
0 to 6 weeks | 9 (10) | 0 (0) | 3 (12) |
Weeks on PEG-IFN therapy | |||
Mean, n (SD) | NA | 11.9 (0.65) | 16.8 (7.8) |
Median, n (IQR) | NA | 12 (12–12) | 21 (10–24) |
PEG-IFN dose-modification | 9 (10) | 3 (5) | 6 (23) |
Ribavirin dose-modification | 21 (23) | 12 (20) | 9 (35) |